HMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia

British Journal of Haematology

Volumn 164, Issue 2, 2014, Pages 212-222

  Roug, Anne S ^a   Larsen, Hanne O ^a   Nederby, Line ^a   Just, Tom ^b   Brown, Gordon ^c   Nyvold, Charlotte G ^a   Ommen, Hans B ^a   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Dako   (Denmark)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Flow cytometry; Leukaemia associated immunophenotype; Minimal residual disease; Quantitative polymerase chain reaction

Indexed keywords

CD123 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; MYELOID INHIBITORY C TYPE LECTIN; STEM CELL FACTOR RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CHILD; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICOLOR FLOW CYTOMETRY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE REGENERATION; VERY ELDERLY;

ACUTE MYELOID LEUKAEMIA; FLOW CYTOMETRY; LEUKAEMIA-ASSOCIATED IMMUNOPHENOTYPE; MINIMAL RESIDUAL DISEASE; QUANTITATIVE POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTIGENS, CD45; BONE MARROW; CHILD; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LECTINS, C-TYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, MITOGEN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891624172     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12614     Document Type: Article

References (43)

1. Al-Mawali, A., Gillis, D., Hissaria, P. & Lewis, I. (2008) Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. American Journal of Clinical Pathology, 129, 934-945.
2. Al-Mawali, A., Gillis, D. & Lewis, I. (2009) The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. American Journal of Clinical Pathology, 131, 16-26.
3. Bachas, C., Schuurhuis, G.J., Assaraf, Y.G., Kwidama, Z.J., Kelder, A., Wouters, F., Snel, A.N., Kaspers, G.J.L. & Cloos, J. (2012) The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia, 26, 1313-1320.
4. Beillard, E., Pallisgaard, N., van der Velden, V.H.J., Bi, W., Dee, R., van der Schoot, E., Delabesse, E., Macintyre, E., Gottardi, E., Saglio, G., Watzinger, F., Lion, T., van Dongen, J.J.M., Hokland, P. & Gabert, J. (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia, 17, 2474-2486.
5. Béné, M.C., Nebe, T., Bettelheim, P., Buldini, B., Bumbea, H., Kern, W., Lacombe, F., Lemez, P., Marinov, I., Matutes, E., Maynadié, M., Oelschlagel, U., Orfao, A., Schabath, R., Solenthaler, M., Tschurtschenthaler, G., Vladareanu, A.M., Zini, G., Faure, G.C. & Porwit, A. (2011) Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia, 25, 567-574.
6. Bonnet, D. (2001) Normal and leukemic CD34-negative human hematopoietic stem cells. Reviews in Clinical and Experimental Hematology, 5, 42-61.
7. Borowitz, M.J., Guenther, K.L., Shults, K.E. & Stelzer, G.T. (1993) Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. American Journal of Clinical Pathology, 100, 534-540.
8. Buccisano, F., Maurillo, L., Spagnoli, A., Del Principe, M.I., Ceresoli, E., Lo Coco, F., Arcese, W., Amadori, S. & Venditti, A. (2009) Monitoring of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology, 21, 582-588.
9. Buccisano, F., Maurillo, L., Del Principe, M.I., Del Poeta, G., Sconocchia, G., Lo-Coco, F., Arcese, W., Amadori, S. & Venditti, A. (2012) Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood, 119, 332-341.
10. ten Cate, B., de Bruyn, M., Wei, Y., Bremer, E. & Helfrich, W. (2010) Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Current Drug Targets, 11, 95-110.
11. Dinardo, C.D. & Luger, S.M. (2012) Beyond morphology: minimal residual disease detection in acute myeloid leukemia. Current Opinion in Hematology, 19, 82-88.
12. van Dongen, J.J.M., Lhermitte, L., Böttcher, S., Almeida, J., van der Velden, V.H.J., Flores-Montero, J., Rawstron, A., Asnafi, V., Lécrevisse, Q., Lucio, P., Mejstrikova, E., Szczepański, T., Kalina, T., de Tute, R., Brüggemann, M., Sedek, L., Cullen, M., Langerak, A.W., Mendonça, A., Macintyre, E., Martin-Ayuso, M., Hrusak, O., Vidriales, M.B. & Orfao, A. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia, 26, 1908-1975.
13. Estey, E.H. (2012) Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology, 87, 89-99.
14. Estey, E. & Döhner, H. (2006) Acute myeloid leukaemia. Lancet, 368, 1894-1907.
15. Feller, N., van der Pol, M.A., van Stijn, A., Weijers, G.W.D., Westra, A.H., Evertse, B.W., Ossenkoppele, G.J. & Schuurhuis, G.J. (2004) MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia, 18, 1380-1390.
16. Gabert, J., Beillard, E., van der Velden, V.H.J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J.M., Cavé, H., Pane, F., Aerts, J.L.E., De Micheli, D., Thirion, X., Pradel, V., González, M., Viehmann, S., Malec, M., Saglio, G. & van Dongen, J.J.M. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 17, 2318-2357.
17. Grimwade, D., Jovanovic, J.V., Hills, R.K., Nugent, E.A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., Rennie, K., Angell, R., Clark, R.E., Solomon, E., Lo-Coco, F., Wheatley, K. & Burnett, A.K. (2009) Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of Clinical Oncology, 27, 3650-3658.
18. Grimwade, D., Vyas, P. & Freeman, S. (2010a) Assessment of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology, 22, 656-663.
19. Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J., Burnett, A.K.; National Cancer Research Institute Adult Leukaemia Working Group (2010b) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354-365.
20. Hokland, P., Ommen, H.B., Nyvold, C.G. & Roug, A.S. (2012) Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission-methodologies in relation to their clinical situation. British Journal of Haematology, 158, 569-580.
21. Hourigan, C.S. & Karp, J.E. (2013) Minimal residual disease in acute myeloid leukaemia. Nature reviews. Clinical Oncology, 10, 460-471.
22. Jin, L., Lee, E., Ramshaw, H., Busfield, S., Peoppl, A., Wilkinson, L., Guthridge, M.A., Thomas, D., Barry, E.F., Boyd, A., Gearing, D.P., Vairo, G., Lopez, A.F., Dick, J.E. & Lock, R.B. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 5, 31-42.
23. Jordan, C.T., Upchurch, D., Szilvassy, S.J., Guzman, M.L., Howard, D.S., Pettigrew, A.L., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D.A., Luger, S.M. & Phillips, G.L. (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia, 14, 1777-1784.
24. Kern, W., Bacher, U., Haferlach, C., Schnittger, S. & Haferlach, T. (2010a) The role of multiparameter flow cytometry for disease monitoring in AML. Best Practice & Research Clinical Haematology, 23, 379-390.
25. Kern, W., Haferlach, C., Schnittger, S. & Haferlach, T. (2010b) Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer, 116, 4549-4563.
26. Kohlmann, A., Grossmann, V., Nadarajah, N. & Haferlach, T. (2013) Next-generation sequencing - feasibility and practicality in haematology. British journal of haematology, 160, 736-753.
27. Lacombe, F., Durrieu, F., Briais, A., Dumain, P., Belloc, F., Bascans, E., Reiffers, J., Boisseau, M.R. & Bernard, P. (1997) Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia, 11, 1878-1886.
28. Langebrake, C., Brinkmann, I., Teigler-Schlegel, A., Creutzig, U., Griesinger, F., Puhlmann, U. & Reinhardt, D. (2005) Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry. Part B, Clinical Cytometry, 63, 1-9.
29. Larsen, H.Ø., Roug, A.S., Just, T., Brown, G.D. & Hokland, P. (2012) Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. Cytometry. Part B, Clinical Cytometry, 82, 3-8.
30. Lucio, P., Gaipa, G., van Lochem, E.G., van Wering, E.R., Porwit-MacDonald, A., Faria, T., Bjorklund, E., Biondi, A., van den Beemd, M.W., Baars, E., Vidriales, B., Parreira, A., van Dongen, J.J., San Miguel, J.F., Orfao, A.; BIOMED-I (2001) BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia, 15, 1185-1192.
31. Majeti, R. (2010) Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene, 30, 1009-1019.
32. Oelschlägel, U., Nowak, R., Schaub, A., Köppel, C., Herbst, R., Mohr, B., Löffler, C., Range, U., Günther, H., Assmann, M., Siegert, E., Wendt, E., Huhn, R., Bräutigam, E. & Ehninger, G. (2000) Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia. Cytometry, 42, 247-253.
33. Ossenkoppele, G.J., van de Loosdrecht, A.A. & Schuurhuis, G.J. (2011) Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. British Journal of Haematology, 153, 421-426.
34. Ostergaard, M., Olesen, L.H., Hasle, H., Kjeldsen, E. & Hokland, P. (2004) WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. British Journal of Haematology, 125, 590-600.
35. Paietta, E. (2012a) Minimal residual disease in acute myeloid leukemia: coming of age. Hematology/The Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2012, 35-42.
36. Paietta, E. (2012b) When it comes to MRD, AML ≠ ALL. Blood, 120, 1536-1537.
37. van der Pol, M.A., Feller, N., Roseboom, M., Moshaver, B., Westra, G., Broxterman, H.J., Ossenkoppele, G.J. & Schuurhuis, G.J. (2003) Assessment of the normal or leukemic nature of CD34 + cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica, 88, 983-993.
38. van Rhenen, A., Feller, N., Kelder, A., Westra, A., Rombouts, E., Zweegman, S., van der Pol, M., Waisfisz, Q., Ossenkoppele, G. & Schuurhuis, G. (2005) High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clinical Cancer Research, 11, 6520-6527.
39. van Rhenen, A., Moshaver, B., Kelder, A., Feller, N., Nieuwint, A.W.M., Zweegman, S., Ossenkoppele, G.J. & Schuurhuis, G.J. (2007a) Aberrant marker expression patterns on the CD34 + CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia, 21, 1700-1707.
40. van Rhenen, A., van Dongen, G.A.M.S., Kelder, A., Rombouts, E.J., Feller, N., Moshaver, B., Stigter-van Walsum, M., Zweegman, S., Ossenkoppele, G.J. & Schuurhuis, G.J. (2007b) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood, 110, 2659-2666.
41. Taussig, D.C., Vargaftig, J., Miraki-Moud, F., Griessinger, E., Sharrock, K., Luke, T., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S.G., Lister, T.A., Gribben, J.G. & Bonnet, D. (2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood, 115, 1976-1984.
42. Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C. & Richards, S. (2013) Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. The Lancet Oncology, 14, 199-209.
43. Voskova, D., Schoch, C., Schnittger, S., Hiddemann, W., Haferlach, T. & Kern, W. (2004) Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry. Part B, Clinical cytometry, 62, 25-38.